NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Retinoic acid (RA) is a key differentiation agent for neuroblastoma, but clinical responses vary significantly.
• No mutations in the RA signaling pathway explain this variable efficacy, indicating other regulatory mechanisms are involved.

Purpose of the Study:

• To investigate the molecular mechanisms underlying variable clinical response to retinoic acid in neuroblastoma.
• To identify novel therapeutic targets for overcoming retinoic acid resistance in aggressive neuroblastoma.

Main Methods:

• A large-scale RNA interference (RNAi) genetic screen was employed to identify factors influencing RA-induced differentiation.
• Analysis of neuroblastoma cell lines and primary tumors for mutations and expression levels of NF1 and ZNF423.
• Investigated the functional relationship between NF1, RAS-MEK signaling, ZNF423, and RA responsiveness.

Main Results:

• Crosstalk between the tumor suppressor NF1 and RA-induced differentiation was identified.
• Loss of NF1 activates RAS-MEK signaling, which represses ZNF423, a coactivator for RA receptors.
• Neuroblastomas with low NF1 and ZNF423 levels exhibit a poor prognosis.
• NF1 mutations were detected in neuroblastoma cell lines and primary tumors.

Conclusions:

• NF1 loss-of-function leads to RAS-MEK pathway activation, downregulating ZNF423 and causing RA resistance in neuroblastoma.
• Targeting MEK signaling downstream of NF1 can restore RA sensitivity in NF1-deficient neuroblastomas.
• This discovery offers a potential therapeutic strategy to improve outcomes for patients with aggressive neuroblastoma.